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Normally Expressed in Embryonic and Neural Stem
Cells in Alloreactive CD81 T Cells Mediating
Graft-versus-Host Disease
Koji Kato,1 Shuaiying Cui,1 Rork Kuick,2 Shin Mineishi,1 Elizabeth Hexner,3
James L. M. Ferrara,4 Stephen G. Emerson,3,5 Yi Zhang1A hallmark of graft-versus-host-disease (GVHD), a life-threatening complication after allogeneic hematopoi-
etic stem cell transplantation, is the cytopathic injury of host tissues mediated by persistent alloreactive
effector T cells (TE). However, the mechanisms that regulate the persistence of alloreactive TE during
GVHD remain largely unknown. Using mouse GVHD models, we demonstrate that alloreactive CD81 TE
rapidly diminished in vivo when adoptively transferred into irradiated secondary congenic recipient mice.
In contrast, although alloreactive CD81 TE underwent massive apoptosis upon chronic exposure to alloan-
tigens, they proliferated in vivo in secondary allogeneic recipients, persisted, and caused severe GVHD. Thus,
the continuous proliferation of alloreactive CD81 TE, which is mediated by alloantigenic stimuli rather than
homeostatic factors, is critical to maintaining their persistence. Gene expression profile analysis revealed
that although alloreactive CD81 TE increased the expression of genes associated with cell death, they acti-
vated a group of stem cell genes normally expressed in embryonic and neural stem cells. Most of these stem
cell genes are associated with cell cycle regulation, DNA replication, chromatin modification, and transcrip-
tion. One of these genes, Ezh2, which encodes a chromatin modifying enzyme, was abundantly expressed in
CD81 TE. Silencing Ezh2 significantly reduced the proliferation of alloantigen-activated CD8
1 T cells. Thus,
these findings identify that a group of stem cell genes could play important roles in sustaining terminally dif-
ferentiated alloreactive CD81 TE and may be therapeutic targets for controlling GVHD.
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Upon antigen-presenting cell (APC) activation,
T cells are ‘‘programmed’’ to undergo clonal expansion,
generating large numbers of effector T cells (TE) while
contracting to minimize their potentially lethal activity
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memory T cells surviving contraction [4,6-8].
However, chronically activated TE can be continually
generated during chronic inflammatory conditions,
such as responses to chronic infections, autoantigens,
and alloantigens. A unique clinical example is graft-
versus-host disease (GVHD), a life-threatening com-
plication after allogeneic hematopoietic stem cell
transplantation (HSCT) [9-13]. A hallmark of GVHD
is the cytopathic injury mediated by persistent
alloreactive TE, which can occur within weeks and
persist for years after transplantation [10-15]. GVHD
therapy, which typically targets TE, has disappointing
response rates (40%) [16]. However, the molecular
mechanisms that regulate the persistence of alloreactive
T cells during GVHD remain largely unknown.
Emerging evidence indicates that a group of stem
cell signals may play important roles in antigen-
experienced memory T cells. CD81 memory T cells
have the ability to self-renew to survive the lifetime of
an individual and can rapidly generate protective TE
upon antigenic rechallenge [1-5]. Gene expression751
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long-term hematopoietic stem cells (HSCs) share
a self-renewal transcriptional program [17]. Further-
more, antigen-stimulated CD81 T cells undergo an
asymmetrical division to regulate the generation of
long-term memory T cells [18]. Thus, memory T cells
are considered to be stem cell-like cells [1,3,4,19].
Interestingly, Wnt/b-catenin signaling, which is
essential for proliferation and self-renewal of adult
stem cells [20], has been shown to regulate the genera-
tion of CD44loCD62LhiCD122hiBcl-2hiSca-1hi CD81
T memory stem cells (TMSC) [21]. These CD8
1 TMSC
have greater ability than either CD44hiCD62Lhi central
memory (TCM) or CD44
hiCD62Llo effector memory T
cells (TEM) to proliferate and generate TE, thereby de-
stroying tumors [21]. This supports our previous obser-
vation that CD81 TMSC are important for sustaining
alloreactive TE mediating GVHD [15]. However, these
data do not explain why alloreactive CD81 TE can
persist and cause severe GVHD in secondary recipients
[14,15]. Given that TE and memory T cells are
developmentally linked to each other [1-6,22], we
asked whether alloreactive TE exposure to chronic
alloantigens proliferate and persist through reactivation
of distinct families of stem cell genes.
Using mouse models of human GVHD directed
against minor histocompatibility antigens (miHAs),
we demonstrate that alloantigenic stimuli rather than
homeostatic factors are critical to sustaining continu-
ous proliferation of alloreactive CD81 TE to counter-
act their massive apoptotic death. We found that
a group of stem cell genes normally expressed in em-
bryonic stem cells (ESCs) and neural stem cells
(NSCs) was activated in these proliferating alloreactive
CD81 TE upon chronic exposure to alloantigens.
Most of these stem cell genes are associated with
DNA replication, cell cycle regulation, chromatin
modification, and transcription. Silencing 1 of these
genes, Ezh2, which encodes an enzyme with methyl-
transferase activity, inhibited the proliferation of
alloantigen-activated T cells. Thus, these stem cell
genes could be important therapeutic targets for mod-
ulating allogeneic T cell responses and GVHD.MATERIALS AND METHODS
Mice
We purchased C57BL/6 (B6; H-2Db, CD45.21),
B6.SJL-Ptprca (B6/SJL, H-2Db, CD45.11), C3H.SW
(H-2Db, CD45.21, and Ly9.11) mice, BALB/b (H-
2Db, CD45.21), B6.b2 microglobulin gene-deficient
mice (B6.B2M
2/2), and BALB/c (H-2Dd, CD45.21)
from Jackson Laboratory (Bar Harbor, ME, USA).
We supplied transplant recipients with drinking water
containing neomycin sulfate and polymyxin B (Sigma,
St. Louis, MO, USA) as previously described [23]. TheInstitutional Animal Care and Use Committee of the
University of Michigan approved all mouse protocols.
Antibodies, Cell Lines, Cytokines and Flow
Cytometry Analysis
All antibodies (Abs) used for immunofluorescence
staining were obtained from BD Bioscience Pharmin-
gen (San Diego, CA, USA). Microbead-conjugated
Abs and streptavidin were purchased from Miltenyi-
Biotech (Auburn, CA, USA), and all recombinant
cytokines including IL-2, IL-4, IL-15, granulocyte-
monocyte colony-stimulating factor (GM-CSF),
stem cell factor (SCF), and tumor necrosis factor-
a (TNF-a) were from R&D Systems (Minnerapolis,
MN, USA). miHA peptide H60/MHC-I dimmers
were prepared by conjugating H60 peptide to MHC-
I dimmers as instructed by the manufacturers (BD Bio-
science). We performed immunofluorescence analyses
of cell surface phenotypes and intracellular cytokines
using FACScan and Canto cytometer (Becton Dickin-
son, San Jose, CA, USA) as previously described [23].
For 5-bromo-20-deoxyuridine (BrdU) incorpora-
tion experiments, mice were given sterile drinking water
containing 0.8 mg/mL BrdU (Sigma) for 3 days. BrdU
labeling was performed as previously described [24]. In
brief, after surface staining, cells were resuspended in
cold 0.15 NaCl, fixed by addition of cold 95% ethanol,
incubated for 30 minutes on ice, and washed with
phosphate-buffered saline (PBS). The cells were then
fixed using fixation solution from BD Cytofix/Cyto-
perm Kit (BD Bioscience) for 30 minutes, pelleted,
and then incubated at 37 C for 30 minutes with 50
KU of DNase I (Sigma) in 0.15 NaCl and 4.2 mM
MgCl2, pH5. After washing, cells were stained with
FITC-conjugated anti-BrdU for 60 minutes at room
temperature, followed by flow cytometry analysis.
Cell Preparations
T cell-depleted bone marrow (TCD BM) was pre-
pared by incubating donor BM with microbead-
conjugated anti-CD4 Ab and anti-CD8 Ab as previ-
ously described [23]. CD81 T cells were magnetically
isolated from spleens and lymph nodes of mice using
microbead-conjugated anti-CD8 Ab (MiniMACS,
Miltenyi Biotech). CD81 T cell subsets were further
separated using fluorescence activated cell sorter (Mo-
Flo, Beckman Coulter, Fullerton, CA, USA). The pu-
rity of each sorted T cell subset was consistently more
than 92%. Donor CD81 T cells were labeled with
fluorescent dye carboxyfluorescein diacetate succini-
midyl ester (CFSE) as described [23]. We prepared
mature DCs from B6 BM as described [25].
GVHD Induction
Mice underwent allogeneic BMT as previously de-
scribed [23]. Briefly, for the C3H.SW anti-B6 mouse
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a split-dose totaling 10.0 Gy from a 137Cs source. We
mixed donor C3H.SW TCD BM (5 106) with or with-
out C3H.SW CD44loCD62Lhi CD81 naı¨ve T cells
(TN) (2.0 106) and transplanted into lethally irradiated
B6/SJL recipients (4 to 8 mice per group per experi-
ment). In some experiments, donor C3H.SW
CD44loCD62Lhi CD81TN (2.0  106) were trans-
planted together with B6/SJL TCD BM (0.5  106)
into lethally irradiated B6/SJL recipients. In the B6/
SJL anti-BALB/b mouse GVHD model, we mixed B6
TCD BM (5  106) with or without CFSE-labeled
B6/SJL CD44loCD62Lhi CD41 and CD81 TN (2.5 
106 T cells for each) and transplanted into lethally irra-
diated BALB/b recipients.
Array-Based mRNA Assays
In 3 repeated experiments, donor alloreactive day 14
CD81 TMSC and TE were highly purified, respectively,
from 4 B6/SJL mice receiving donor CD44loCD62Lhi
CD81 TN derived from 6 C3H.SW mice. Donor
CD44loCD62Lhi CD81 TN were highly purified from
pooled CD81 T cells of 2 C3H.SW mice in 3 separate
experiments. Total RNA was prepared from these
T cell subsets using TRIzol (Invitrogen Life Technolo-
gies, Carlsbad, CA, USA). Biotinylated cDNA was
prepared for each sample from 600 ng total RNA using
2 rounds of reverse-transcription and T7 promoter-
based in vitro transcription following hybridization to
the arrays. Hybridization, scanning, and image analysis
of the arrays were performed according to the manufac-
turer’s protocol (Affymetrix, Santa Clara, CA, USA).
Mouse Genome 430A 2.0 Arrays containing 22,690
probe sets (Affymetrix) were used to broadly compare
the transcription profile of CD81 TE and TMSC to
that of TN. The array data are available from Gene
Expression Omnibus, accession GSE13743. Using
publicly available software [26], we computed trimmed
averages of PM-MM differences for each probe set
and quantile-normalized these after scaling the arrays
to give average probe set values of 1500 units. We
then log-transformed using log (max[x150;0] 1 50).
Using a 1-way analysis of variance (ANOVA) model
we selected transcripts that gave P\ .01 for comparing
pairs of groups that also gave at least a 1.5-fold differ-
ence from the means for the paired groups, computed
based on differences in the means of log-transformed
data. We collapsed probe sets to 13,142 distinct
genes using Entrez gene IDs. Data can be viewed
from the following Web site: http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?token5tjunpugmcoqomxc
&acc5GSE13743.
Western Blot
Samples were separated on a 12% SDS-PAGE gel
and transferred onto a nitrocellulose membrane (Milli-pore Corporation, Bedford, MA, USA). After an over-
night incubation at 4 C with primary Abs, membranes
were washed 5 times and probed with HRP-
conjugated secondary Ab (Vector Laboratories, Bur-
lingame, CA) for 1 hour at room temperature, and im-
munoreactivity was detected by chemiluminescence
(GE Healthcare, Piscataway, NJ).
Real-Time Reverse Transcription Polymerase
Chain Reaction (RT-PCR)
The total RNA was extracted from the sorted
CD81 T cell subsets using TRIzol (Invitrogen Life
Technologies). Real-time RT-PCR was performed us-
ing a SYBR green PCR mix (ABI Biosystem, Foster
City, CA) in the Realplex2 Eppendorf Real-time PCR
instrument (Eppendorf AG, Westbury, NY, USA).
Gene expression levels were calculated relative to the
18S gene. The primer sequences used for real-time
RT-PCR include: 18S (50-GCTGCTGGCACCA-
GACTT and 30-CGGCTACCACATCCAAGG),
Ifng (50-ATGAACGCTACACACTGCATC and 30-
CCATCCTTTTGCCAGTTCCTC), Granzyme B
(50-CCACTCTCGACCCTACATGG and 30-GGC
CCCCAAAGTGACATTTATT), Ezh2 (50-TGCCT
CCTGAATGTACTCCAA and 30-AGGGATGTA
GGAAGCAGTCATAC), Tacc3(50-GAGATGGG-
GAAGTCCGTTGATG and 30-CTCTGCTTGGG
CCTTGCTGTGT), Birc5 (50-AACTACCGCAT
CGCCACCTTC and 30-TTCTTCCATCTGCTT
CTTGACA), Hells (50-GGGGAGTACCTGGACC
TTTTCTTG and 30- CTGCAGTGTCCCTTGTC
TTTTGTG), Pd1(50- ACCCTGGTCATTCACTT
GGG, and 30-CATTTGCTCCCTCTGACACTG),
p18 (50- GTAAACGTCAACGCTCAAAATGG and
30-GAACCTGGCCAAGTCGAAGG), Casp4 (50-AC
AAACACCCTGACAAACCAC and 30-CACTGCG
TTCAGCATTGTTAAA), and Bcl2 (50-GTCGCTA
CCGTCGTGACTTC and 30-CAGACATGCACC
TACCCAGC).
Lentiviral Vector Construction and Viral
Production
Doxyclycline (Dox) regulated lentiviral vector
pLVPT-rtTRKRAB2SM2 (pLVPToff) was obtained
from Addgene (Cambridge, MA) [27]. We cloned
short-hairpin RNA duplex that specifically targets
Ezh2 (Ezh2-shRNA, 50CGCGTCCCCAAGAGGT
TCAGAAGAGCTGTTCAAGAGACAGCTCTTCT
GAACCTCTTTTTTTGGAAAT30) [28] into this
pLVPToff, in which Ezh2-shRNA and GFP are sepa-
rately driven by H1 promoter and phosphoglycerate
kinase (PGK) promoter (named Ezh2-shRNA/GFP-
pLVPToff), as previously described [27]. Lentiviral
vector encoding scrambled shRNA and GFP was
generated as control (named Con-shRNA/GFP-
pLVPToff). In the absence of Dox, Ezh2-shRNA and
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press the expression the transcription of both shEzh2
and GFP [27]. Production of lentiviruses was done in
293T cells as described [27].
In Vivo Reconstitution of T Cells with Inducible
Knockdown of Ezh2
C-kit1 hematopoietic cells were magnetically iso-
lated from B6 mice and infected with Ezh2-shRNA-
pLVPToff in vitro as previously described [29],
followed by transplantation into lethally irradiated
B6 mice. To repress the expression of Ezh2-shRNA
in HSCs during their hematopoietic and thymic re-
constitution, all of these recipient mice were given
sterile water containing Dox (2 mg/mL) from day
22 to 12 weeks after transplantation. HSCs infected
with Control-shRNA-pLVPToff were transplanted as
control. Twelve weeks after transplantation, Dox was
removed from these mice to induce the expression of
Ezh2-shRNA. Seven days later, CD81 T cells were
isolated from the spleens and lymph nodes of these
mice. GFP1CD81 T cells expressing Ezh2-shRNA
(named Ezh2-shRNA GFP1CD81 T cells), or Con-
trol shRNA (named Control-shRNA GFP1CD81 T
cells) were sorted using the BD FACSAria II cell sorter
(BD Bioscience).
Ex Vivo Stimulation of CD81 T Cells
Sorted Ezh2-shRNA GFP1CD81 TN and control-
shRNA GFP1CD81 TN were stimulated with
anti-CD3 Ab and anti-CD28 Ab (2.5 mg/mL for each)
in 96-well plate as previously described [14,15,30]. In
some experiments, unfractionated splenic mononuclear
cells that contained Ezh2-shRNA GFP1CD81 T cells
were cultured in the presence of allogeneic DCs or
IL-7. The recovery number of GFP1CD81 T cells was
assessed by flow cytometry analysis.
Statistical Analysis
Survival in different groups was compared by using
the log-rank analysis. Comparison of 2 means was ana-
lyzed using the 2-tailed unpaired Student t-test. Statis-
tical analysis from the gene array is indicated in the text.RESULTS
Alloantigen-Induced Continuous Proliferation Is
Essential to Maintaining Chronically Activated
Alloreactive CD81 TE
Because CD81 TE are known to be ‘‘terminally
differentiated’’ and short-lived cells [1-6], we first
determined under what conditions alloreactive CD81
TE were able to persist in vivo and cause GVHD. We
transplanted CFSE-labeled donor CD81 TN from
normal C3H.SW mice together with B6/SJL TCD
BM into lethally irradiated B6/SJL recipients. Thisallowed us to strictly track the fate of infused donor ma-
ture T cells while inducing GVHD [15]. By day 14 after
transplantation, donor alloreactive CD81 TE became
the dominant population (.80%) (named day 14
CD81 TE, Figure 1A). They had undergone extensive
division and produced significantly higher levels of
IFN-g and Granzyme B (Gzmb) (Figure 1A and B).
When later adoptively transferred into lethally irradi-
ated secondary allogeneic B6/SJL mice, all the day 14
CD81 TE had extensively divided in vivo, expressed
high levels of proliferating antigen Ki67 7 days after
transplantation (Figure 1C). BrdU incorporation anal-
ysis showed that about 22% of day 14 CD81 TE
derived from primary GVHD recipient mice and
76% of alloreactive CD81 TE recovered from second-
ary recipients of day 14 CD81 TE had incorporated
BrdU (Figure 1D). These results suggest that a substan-
tial proportion of day 14 CD81TE are dividing during
GVH reaction.
Interestingly, 4-fold fewer donor T cells were re-
covered from secondary recipients of day-14 CD81
TE than that of donor CD8
1 TN (Figure 1E). This
was associated with significantly increased apoptotic
death of donor T cells in day 14 CD81 TE recipients
compared to CD81 TN recipients (Figure 1F). Fur-
thermore, adoptive transfer of these day 14 CD81
TE caused GVHD in secondary recipients, with 70%
of them dying from the disease by day 75 after trans-
plantation (Figure 1G). Thus, upon chronic exposure
to alloantigens, alloreactive CD81 TE continuously
proliferated to persist while undergoing increased
apoptotic death. However, all alloreactive CD81 TE
diminished in vivo without causing GVHD when
adoptively transferred into secondary B6.B2M
2/2
mice (data not shown). These results suggest that
allogeneic stimuli could be essential to sustaining
alloreactive CD81 TE.
In lethally irradiated allogeneic recipient mice, both
alloantigens and lymphopenia-related homeostatic
factors (eg, self-antigen peptides and cytokines IL7
and IL-15) [31] could be responsible for the prolifera-
tion of alloreactive CD81TE. To assess the possible im-
pact of alloantigens versus homeostatic factors in
regulating the persistence of alloreactive TE, we used
the CD41 T cell-dependent B6 anti-BALB/b GVHD
model, in which miHA H60-specific (H601) CD81
TE could be tracked using miHA peptide/MHC class-
I dimmer staining (Figure 2A) [14,32,33]. We highly
purified H601CD81 TE at day 12 posttransplantation
from GVHD BALB/b mice receiving donor B6/SJL
TN (CD45.1), labeled with CFSE, and adoptively
transferred together with B6/SJL CD41 TE and
donor B6 TCD BM into lethally irradiated congenic
B6 (CD45.21) mice and allogeneic BALB/b mice.
Lethal irradiation of congenic B6 mice creates
a lymphopenic environment that might induce
homeostatic proliferation and survival of adoptively
Figure 1. Alloreactive CD81 TE are highly replicating cells causing GVHD. (A) CFSE-labeled donor CD8
1 TN (2 106) derived from normal C3H.SW
mice were transplanted with B6/SJLTCD BM (0.5 106) into lethally irradiated B6/SJL mice. Donor CD81 T cells were recovered at day 14 after trans-
plantation from the spleen and lymph node of 3 recipients, enumerated, and stained for flow cytometric analysis. Histograms show the cell division based
on CFSE dilution and production of IFN-g by CD81 TMSC, TCM, and TE. Data are representative of 3 independent experiments. (B) Real-time RT-PCR
analysis shows the relative mRNA expression of selected genes in donor day 14 CD81 TE, TCM and TMSC. Data are representative of 3 independent
experiments. (C, D) Day 14 CD81 TE were relabeled with CFSE and adoptively transferred into lethally irradiated secondary B6/SJL mice. CFSE-
labeled C3H.SW CD81 TN were transferred as controls. Donor T cells were recovered at day 7 after adoptive transfer, enumerated, and analyzed
for flow cytometry. Histogram shows the cell division of indicated cells. Nonstimulated CFSE-labeled CD81 TN were used as nondividing cell control.
Contour plots show the expression of Ki67 (C). For BrdU labeling, secondary recipient mice were given drinking water containing BrdU for 3 days prior
to the end of the experiments. At day 7, donor cells were recovered, stained with BrdU, and analyzed by flow cytometry. Dot plots show the labeling of
BrdU in gated CD81 TE population (mean6 SD) (D). (E, F) As described in C, the number of donor T cells recovered from these secondary recipients (n
5 3 for each group) was calculated (E) and the percentage of apoptotic cell was shown (F). Data are representative of 2 independent experiments. (G)
Donor C3H.SW TCD BM (5 106) were transplanted alone, or with donor day 14 CD81 TE (0.5 106) and donor CD81 TN (1.0 106) into lethally
irradiated secondary B6/SJL mice. Survival of animals was analyzed with the Kaplan-Meier method. *P\.05, significant difference.
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of miHA H60, whereas lethally irradiated allogeneic
BALB/b mice could provide persistent alloantigen-
stimulation in addition to homeostatic factors.
We found that donor H601CD81 TE were read-
ily detected in the peripheral blood of secondary allo-
geneic BALB/b recipients (43.3 6 19%) by day 14
after transplantation, but not in that of secondary
congenic B6 recipients (0.1 6 0.3%) (Figure 2B and
C). Forty-three days after transfer, allogeneic
BALB/b recipients showed about 80-fold more pro-
liferating H601CD81 T cells than B6 congenicrecipients (Figure 2D). These donor H601CD81
TE from secondary allogeneic BALB/b recipients ex-
pressed high levels of CD69, suggesting a recent an-
tigenic stimulation (Figure 2E). Furthermore, they
produced high levels of IFN-g and Granzyme B
(Figure 2E) and caused GVHD in these secondary al-
logeneic BALB/b mice (Figure 2F). In separate exper-
iments, we observed that adoptive transfer of donor
alloreactive CD81 TE alone also caused GVHD in
secondary allogeneic BALB/b mice (Figure 2F), sug-
gesting that CD4-help is not essential to already dif-
ferentiated CD81 TE to mediate GVHD. None of
Figure 2. Proliferation and persistence of alloantigen-specific CD81 TE depend on the presence of chronic alloantigen. (A) CFSE-labeled donor T cells
(CD41 and CD81 T cells, 3  106 for each) from normal B6/SJL mice (CD45.1) were transplanted, together with B6 TCD BM (CD45.2, 5 106), into
lethally irradiated (10 Gy) primary BALB/b recipients (CD45.2). Dot plots show percent of host miHAH60-specific CD81TE that were recovered at day
12 after transplantation from spleens and livers of primary GVHDBALB/b recipients (n5 4) of B6/SJLTCDBM and B6/SJLT cells. Data are representative
of 3 independent experiments. (B, C, D) Donor alloreactive B6/SJL H601CD81 TE (5  104) and CD41 T cells (3  105) were isolated 12 days after
transplantation, respectively, from these primary GVHD BALB/b recipients (CD45.2) of B6/JL T cells, relabeled with CFSE, and adoptively transferred
together with B6 TCD BM (5  106) into lethally irradiated secondary BALB/b recipients and congenic B6 recipients (CD45.2), respectively. The per-
centage of donor alloreactive H601CD81 TE in the peripheral blood of these secondary recipients at day 14, 28, and 43 after adoptive transfer (B). Dot
plots show the fraction of H601CD81 TE in the peripheral blood (C). Donor alloreactive H60
1CD81 TE recovered at day 43 from secondary recipients
were calculated (D). Data are presented as mean6 SD. *P\.01. (E) Histograms show the surface markers of donor H601CD81 TE isolated from the
secondary allogeneic BALB/b mice (left), and dot plots show the production of IFN-g and GZMB (right). Data shown in B, C, D, and E are representative
of 2 independent experiments. (F) Survival rate of animals was analyzed by the Kaplan-Meier Method. *P\.05, significant difference.
756 Biol Blood Marrow Transplant 16:751-771, 2010K. Kato et al.these congenic B6 mice receiving donor alloreactive
CD81 TE developed clinical signs of GVHD (data
not shown). Thus, alloantigenic stimuli rather than
homeostatic factors are critical to the continual pro-
liferation and persistence of alloreactive CD81 TE
during GVH reaction.Gene Expression Profiles of Alloreactive
CD81 TE
To understand the molecular mechanisms by which
alloreactive CD81TE acquire the ability to continually
proliferate upon chronic exposure to alloantigens, we
used Affymetrix Mouse Genome A430A 2.0 Array to
broadly compare the gene expression profiles of day
14 CD81 TE to that of CD8
1 TN and CD8
1 TMSC(Figure 3A). Compared to TN, a total of 2744 distinct
genes were upregulated (1359) or downregulated
(1385) in CD81 TE by a 1.5-fold that gave a P\ .01
value for comparing pairs of groups. As predicted by
our experimental data [14,15] and others [12,34],
relative to CD81 TN and TMSC, CD8
1 TE expressed
significantly higher levels of genes known to be
important for effector functions, including effector
molecules, chemokines, and chemokine receptors
(Table 1). As expected, many other genes engaged in
T cell receptor (TCR) signaling pathway, glycolysis,
MAPK pathway, and cell adhesion were also altered
in CD81 TE (Table 1).
To better define a specific gene signature of allo-
reactive T cells, we further tested each list of distinct
genes for overrepresentation in 507 lists of Gene
Figure 3. Array based mRNA arrays of alloreactive CD81 T cells. (A) Donor CD44loCD62Lhi CD81 TN (2 106) from C3H.SWmice (CD45.2) were
transplanted with B6/SJLTCD BM (0.5 106) into lethally irradiated B6/SJL mice (CD45.1). Donor CD81 T cells were recovered at day 14 after trans-
plantation from the spleens and lymph nodes of these recipients, magnetically purified, and stained with indicated Abs for flow cytometry cell sorting.
Affymetrix Mouse Genome 430A 2.0 array was used to broadly compare the transcription profiles of these CD81 TMSC and TE to that of TN cells. (B)
Real-time RT-PCT analysis shows the relative expression of mRNA in each T cell subset. Data are representative of 3 independent preparations of
alloreactive T cells.
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genes present on the array (Affymetrix Web site), as
well as for 190 lists of pathways from the Kyoto Ency-
clopedia of Genes and Genomes (KEGG, http://
www.genome.jp/kegg/). Compared to both CD81
TN and TMSC, CD8
1TE demonstrated a signature ex-
pression of genes related to cell cycle, mitosis, apopto-
sis, and transcription and translation (Table 2).
Detailed analysis revealed that alloreactive CD81
TE showed decreased expression of antiapoptotic
gene Bcl2, but had increased genes related to apopto-
sis, including Pdcd1 (also named Pd1), Klrg1, Casp1,
Casp3, Caps4, Casp7, Bax, and Bad (Table 1). In con-
trast, CD81TMSC expressed higher levels of Bcl2 than
both TN and TE, whereas it only minimally changed in
the expression of other pro-apoptotic genes (Table 1
and Figure 3B). When compared to CD81 TN,
CD81 TE show significantly decreased expression of
genes related to ribosome biogenesis and assembly, ri-
bosome, translation, and transcription (Table 2). Real-
time RT-PCR validated the expression some of these
genes (Figure 3B).
Notably, alloreactive CD81 TE also had 150-fold
more expression of p18Ink4c (encoded by Cdkn2c) than
CD81 TN and 15-fold than CD8
1 TMSC (Figure 3B).
Previous studies have shown that p18Ink4c plays a critical
role in negatively regulating cell proliferation and sur-
vival [35-38]. The loss of p18Ink4c in T cells causes
their hyperproliferation response and proliferation
disorder [38,39].
Altogether, this transcriptional signature con-
firmed that alloreactive CD81TE are replicating cells,
but are more likely susceptible than CD81 TMSC toapoptotic death and senescence, consistent with our
previous observations [15].Alloreactive CD81 TE Activate Stem Cell
Transcriptional Programs
Next we tested 1687 curated gene lists from Mo-
lecular Signature Database v2 (MSigDB v2) [40] to in-
quire which transcriptional program(s) could be
associated with the continuous proliferation property
of alloreactive CD81 TE. Based on 1-sided Fisher’s
exact test, we identified that transcripts increased
in CD81 TE were significantly enriched in lists of
genes increased in NSCs (345 of 1636 genes, P 5 7.3
 10244) and ESCs (227 of 1193 genes, P 5 1.7 
10221) (Figure 4A), which were identified by
Ramalho-Santos et al. [41]. These alloreactive CD81
TE-related ESC genes and NSC genes are listed in
Table 3 and Table 4. Among them, 171 genes were
shared by ESCs and NSCs, 56 appeared in ESCs,
and 174 were found only in NSCs. Thus, 401 of
1369 (29%) of transcripts that were increased in allor-
eactive CD81 TE were enriched for ESCs and/or
NSCs (Figure 4A). In contrast, transcripts decreased
in CD81 TE were overrepresented among HSC-
related genes (253 of 1279, 19.8%, P 5 2.2  10225)
(Figure 4A).
Like TE, the 543 transcripts increased in TMSC ver-
sus TN showed significant overrepresentation of ESC-
and NSC-related genes (P 5 4.8  1025 and 3.4 
1026, respectively) (Figure 4A). Notably, 72% of ESC-
and NSC-related genes selected as increased in TMSC
were also increased in TE (87 of 121 genes; Tables 3
Table 1. Altered Transcripts in TMSC and TE Compared to TN
Gene Symbols Gene ID#
Fold Change
Gene Symbols Gene ID#
Fold Change
Gene Symbols Gene ID#
Fold Change
TMSC/TN TE/TN TMSC/TN TE/TN TMSC/TN TE/TN
Effector function Glycolysis/Gluconeogenesis mTOR pathway
Gzmb 14939 38.3 306.4 Hk2 15277 2 7.1 Rps6kb2 58988 2.7
Ifng 15978 4.2 211 Tpi1 21991 1.9 4.1 Akt1 11651 2.1
Fasl 14103 66.3 Eno3 13808 4 Eif4e2 26987 2
Klrk1 27007 2.9 3.3 Gapdh 14433 1.5 3.8 Rps6ka1 20111 1.7
Prf1 18646 3 Acyp2 75572 1.8 2.4 Eif4b 75705 21.9
Tnfsf10 22035 2.7 Pfkp 56421 1.5 1.9 Tsc1 64930 22
Klra3 16634 2.3 Bpgm 12183 1.6 Rps6ka2 20112 22.9
Chemokine-chemokine receptor interactions MAPK signaling pathway Adhesion and transendothelial migration
Ccl5 20304 15.9 453.5 Stmn1 16765 5 19.3 Cd44 12505 14.2
Ccl4 20303 69.6 Dusp1 19252 1.8 4.9 Hmmr 15366 7.2
Ccl3 20302 42 Map3k8 26410 7.6 3.4 Itgb1 16412 5.6
Ccr5 12774 4.7 32.8 Gadd45b 17873 3.2 Spp1 20750 4.5
Ccr2 12772 10.8 Gadd45g 23882 15.3 2.7 Itga4 16401 2.7
Cxcr3 12766 4.1 8.3 Dusp3 72349 1.8 2.5 Sdc4 20971 2.5
Cx3cr1 13051 4.8 Mapkapk2 17164 1.8 Itgav 16410 2.4
Xcl1 16963 4.7 Mapk3 26417 1.8 Lamc1 226519 2
Cxcl10 15945 3.1 Map2k3 26397 1.7 Itga3 16400 2
Cxcl10 15945 3.1 Mapk8 26419 21.6 Npnt 114249 1.9
Ccr6 12458 2.9 Mapk14 26416 21.6 Itgb2 16414 1.9
Ccl6 20305 2.7 Map2k6 26399 21.6 Vcl 22330 1.7
Ccr7 12775 229.1 Dusp2 13537 21.6 Tnc 21923 1.6
Cytokine-cytokine receptor interactions Jak-STAT signaling pathway Pxn 19303 1.5
Il10ra 16154 1.7 9.9 Pim1 18712 2.3 2.3 Apoptosis
Csf1 12977 22 6.4 Jak3 16453 1.8 1.9 Casp3 12367 5.4
Il2rb 16185 1.7 6.3 Socs5 56468 21.7 21.7 Capn2 12334 2.3
Il10 16153 6.1 Stat6 20852 21.7 Bid 12122 2.2
Csf2 12981 4.7 Stat1 20846 2 21.8 Apaf1 11783 2.2
Il15ra 16169 2 2.5 Jak1 16451 21.5 21.8 Casp7 12369 2.1
Il12rb1 16161 1.9 2.5 Socs3 12702 2.6 22.4 Bax 12028 1.8
Il4ra 16190 22.8 Socs1 12703 1.9 Bcl2l1 12048 1.6
Il6st 16195 21.6 24.3 Myc 17869 1.5 Bad 12015 1.5
Il7r 16197 21.9 27.3 Toll-like receptor signaling pathway Bcl2 12043 2 21.5
Il6ra 16194 218.6 Tlr7 170743 2.6 Trp53 22059 1.9
Il10rb 16155 1.6 Tlr6 21899 1.5
TCR signaling TCR signaling TCR signaling
Tbx21 57765 8.8 21.5 Cdc42 12540 1.6 Ikbkb 16150 22.5
Map3k8 26410 7.6 3.4 Hras1 15461 1.5 1.5 Pak1 18479 25.8
Nfatc1 18018 2.6 Ikbkg 16151 21.5 Pdk1 228026 26.3
Fyn 14360 2.1 Itk 16428 21.5 22 Jun 16476 6.1
Ppp3cc 19057 1.6 1.7 Map3k14 53859 21.5 22.2 Fos 14281 4
Zap70 22637 1.7 Tec 21682 22.5 Lcp2 16822 21.6
TCR indicates T cell receptor.
758 Biol Blood Marrow Transplant 16:751-771, 2010K. Kato et al.and 4). Thus, despite their different proliferation
capability, both alloreactive CD81 TE and TMSC share
some common stem cell transcriptional programs.
To validate our observations using an unsupervised
approach, we obtained Sarkar’s et al. dataset
(GSE10239) [42], fit 1-way ANOVA models, and per-
formed probe-set selections identical to those of our
array data. In their experiments, both KLRG1Int and
KLRG1High P14 CD81 TE specific to lymphocytic
choriomenigitis (LCMV)-gp33 showed probe set dif-
ferences compared to TN that had significantly over-
laps with probe sets that we found to differ between
alloreactive CD81 TE and TN in our GVHD model
(P \ 102200, by Fisher’s Exact test in both cases).
Most importantly, as with our alloreactive CD81 TE,
P14 CD81 TE highly enriched for ESC- and NSC-
related genes (Figure 4B). In contrast, P14 CD81
memory cells decreased the expression of ESC- andNSC-related genes, whereas it activated genes en-
riched for HSCs (Figure 4B). These data indepen-
dently confirmed our gene microarray data.Characterization of Stem Cell Genes Activated
in Alloreactive CD81 TE
These observations were surprising to us because
CD81 TE have been believed to be terminally differ-
entiated cells [1,43]. To understand what these
CD81 TE-related stem cell genes were, we assigned
these genes to several functional categories by
filtering for keywords in the GO terms as previously
described by Ramalho-Santos et al. [41]. As shown in
Table 5, we found that CD81 TE shared the similarity
with ESCs and NSCs in the expression of genes asso-
ciated with: (1) regulation of cell cycle, (2) resistance to
stress, (3) chromatin modification and transcription/
Table 2. Most Significantly Enriched GOTerms and KEGG Pathways
A) Tests of 507 Gene Ontology (GO) Biological Process Terms with at Least 10 Genes Present on the Arrays
Comparison Direction
Number of Probe Sets
Selected (of 22,690)
Number
of Distinct Genes
Selected (of 13,142) GO Term Title
Number of Genes with GO
Term on the Array
Number of Those Genes
Selected P-Value
Average Number of GO
Terms This Good in 100
Permutations
TMSC versus TN up in TMSC 672 543 cell cycle 335 41 4.1E-10 0
immune response 263 29 1.4E-06 0
DNA replication 96 16 1.8E-06 0
mitosis 109 17 2.2E-06 0
cell division 173 22 2.6E-06 0
regulation of progression
through cell cycle
185 20 8.1E-05 0.003
TMSC versus TN up in TN 545 448 transcription 1125 72 1.1E-07 0
regulation of transcription,
DNA-dependent
1486 86 4.6E-07 0
TE versus TMSC up in TE 1486 1098 cell cycle 335 102 1.5E-32 0
mitosis 109 53 1.1E-28 0
cell division 173 66 1.1E-27 0
DNA replication 96 40 6.7E-19 0
apoptosis 296 54 3.1E-08 0
DNA replication initiation 13 9 1.0E-07 0
TE versus TMSC up in TMSC 1372 1036 ribosome biogenesis and
assembly
47 21 9.6E-12 0
translation 259 51 7.5E-10 0
TE versus TN up in TE 1817 1359 cell cycle 335 109 2.6E-29 0
mitosis 109 52 2.9E-23 0
cell division 173 67 3.5E-23 0
DNA replication 96 41 1.8E-16 0
DNA replication initiation 13 10 2.9E-08 0
apoptosis 296 59 5.1E-07 0
DNA recombination 35 13 2.4E-05 0
regulation of progression
through cell cycle
185 38 2.6E-05 0
TE versus TN up in TN 1837 1359 ribosome biogenesis and
assembly
47 18 5.3E-07 0
translation 259 49 3.3E-05 0
transcription 1125 158 6.9E-05 0
B) Tests of 190 KEGG Pathways
Comparison Direction
Number of Probe Sets
Selected (of 22,690)
Number of
Distinct Genes
Selected (of 13,142) Pathway Title
Number of
Genes in
Pathway on the Array
Number of Those
Genes Selected P-Value
Average Number of
Pathways This Good
in 100 Permutations
TMSC versus TN up in TMSC 672 543 Cell cycle 102 16 4.1E-06 0
Pyrimidine metabolism 80 12 1.0E-04 0
Jak-STAT signaling pathway 122 14 5.0E-04 0.02
TMSC versus TN up in TN 545 448 Wnt signaling pathway 133 11 5.8E-03 0.3
(Continued )
B
io
l
B
lo
o
d
M
a
rro
w
T
ra
n
sp
la
n
t
1
6
:7
5
1
-7
7
1
,
2
0
1
0
7
5
9
S
te
m
C
e
ll
S
ign
a
ls
in
A
llo
re
a
ctive
T
C
e
lls
T
a
b
le
2
.
(C
on
ti
nu
ed
)
B
)
T
e
st
s
o
f
1
9
0
K
E
G
G
P
a
th
w
a
y
s
C
o
m
p
ar
is
o
n
D
ir
ec
ti
o
n
N
u
m
b
er
o
f
P
ro
b
e
Se
ts
Se
le
ct
ed
(o
f
2
2
,6
9
0
)
N
u
m
b
er
o
f
D
is
ti
n
ct
G
en
es
Se
le
ct
ed
(o
f
1
3
,1
4
2
)
P
at
h
w
ay
T
it
le
N
u
m
b
er
o
f
G
en
es
in
P
at
h
w
ay
o
n
th
e
A
rr
ay
N
u
m
b
er
o
f
T
h
o
se
G
en
es
Se
le
ct
ed
P-
V
al
u
e
A
ve
ra
ge
N
u
m
b
er
o
f
P
at
h
w
ay
s
T
h
is
G
o
o
d
in
1
0
0
Pe
rm
u
ta
ti
o
n
s
T
E
ve
rs
u
s
T
M
S
C
u
p
in
T
E
1
4
8
6
1
0
9
8
C
el
l
cy
cl
e
1
0
2
3
9
6
.5
E
-1
7
0
N
at
u
ra
l
ki
lle
r
ce
ll-
m
ed
ia
te
d
cy
to
to
x
ic
it
y
1
0
1
2
3
7
.3
E
-0
6
0
T
E
ve
rs
u
s
T
M
S
C
u
p
in
T
M
S
C
1
3
7
2
1
0
3
6
R
ib
o
so
m
e
7
1
2
9
1
.9
E
-1
4
0
T
E
ve
rs
u
s
T
N
u
p
in
T
E
1
8
1
7
1
3
5
9
C
el
l
cy
cl
e
1
0
2
4
5
1
.3
E
-1
8
0
P
ro
te
as
o
m
e
3
0
1
3
3
.2
E
-0
6
0
N
at
u
ra
lk
ill
er
ce
ll-
m
ed
ia
te
d
cy
to
to
x
ic
it
y
1
0
1
2
5
2
.5
E
-0
5
0
T
E
ve
rs
u
s
T
N
u
p
in
T
N
1
8
3
7
1
3
5
9
R
ib
o
so
m
e
7
1
2
6
5
.0
E
-0
9
0
T
M
S
C
in
d
ic
at
es
T
m
em
o
ry
st
em
ce
lls
;
T
N
,
n
aı¨
ve
T
ce
lls
;
T
E
,
ef
fe
ct
o
r
T
ce
lls
;
K
E
G
G
.
K
yo
to
E
n
cy
cl
o
p
ed
ia
o
f
G
en
es
an
d
G
en
o
m
es
.
760 Biol Blood Marrow Transplant 16:751-771, 2010K. Kato et al.translation regulation, (4) cell survival and death, (5)
signaling, and (6) others. In cell cycle category,
CD81 TE increased both negative (eg, p18
Ink4c and
p21Cip1) and positive cell cycle regulators (eg, Ccna
and Ccnb). Interestingly, after removing all these cell
cycle genes from our array data and Ramalho-Santos’s
stem cell data set [41], we found that the rest of tran-
scripts increased in alloreactive CD81 TE remained
significant overrepresentation of ESC- and NSC-
related genes (P \ 5.0215, by Fisher’s Exact test in
both cases). Our further evaluation of Sarkar’s et al.
[42] and Ramalho-Santos’s et al. [41] data sets without
these cell cycle genes also revealed significant enrich-
ments in P14 CD81 TE for ESC- and NSC-related
transcripts (P\ 4.2282 in both cases). Thus, cell cycle
genes are not the only attributes to the similarity of
gene expression between CD81 TE and embryonic
and neural stem cells.
Genes engaged in resistance to stress represented
were a large group of stem cell transcripts activated in
CD81 TE. This group of genes included transcripts of
DNA replication and repair, ubiquitin/proteasome, me-
tabolism, and electron transport (Table 5). These genes
are considered to be related to the stress condition of
stem cells [41]. For example, genes including Coq7,
Ube2l3, Nedd4, and Psma play important role in
modifying abnormal or short-lived proteins [44,45].
DNA repair gene Rad51 is critical to maintaining
chromosomal stability and preventing genetic
mutation potentially occurring during cell division
[41,46]. Genes associated with metabolisms, such as
Gldc and Gsto1, are critical to amino acid and
antioxidant metabolism [47,48]. The functions of these
genes in T cells and stem cells remain largely unknown.
Another important finding was that CD81TE acti-
vated many genes engaged in DNA methylation, chro-
matin modification, transcription, and survival in ESCs
and NSCs. For example, Uhrf1 protein forms com-
plexes with DNA methyltransferase Dnmt1, which
may result in an inheritable DNA methylation [49].
Hells (also known as Lsh) protein associates with
Dnmt3a and Dnmt3b in embryonic cells for DNA
methylation and transcription [50]. Tacc3 protein can
activate gene transcription even prior to demethylation
[51]. Birc5 (also known as Survivin), is an apoptosis in-
hibitor in both normal and malignant cells [52]. Ezh2,
which encodes a chromatin modifying enzyme with
methyltransferase activity, orchestrates gene expression
in both embryonic and adult stem cells [53-55]. The
representative gene expression of these chromatin
modifiers and transcriptional regulators were shown
in Figure 5A, and validated by real-time RT-PCR
(Figure 5B). Thus, genes in this category have multiple
roles in controlling cell fate, self-renewal, differentia-
tion, survival, and memory function.
Finally, we noted that CD81 TE did not activate
those genes associated with pluripotency of ESCs,
Figure 4. Acquisition of stem cell transcriptional programs in alloreactive CD81 T cells. (A) Genes distinctively expressed by CD81 TMSC and TE rel-
ative to TN were analyzed for functional set enrichment analysis using curated gene lists from the Ramalho-Santos’s array data. (B) Acquisition of stem
cell transcriptional programs in P14 LCMV-gp33-specific CD81 T cells. Genes differentially expressed by CD81 TE-KLRG1
Hi, CD81 TE-KLRG1
Hint and
CD81memory T cells relative to TNwere analyzed for enrichment for the same stem cell gene lists. Sizes of stem cell gene lists differ slightly from that in
Figure 4A because Sarkar’s et al. study used Affymetrix Mouse_430_2, which also had slightly different probe-set annotation than our arrays.
Biol Blood Marrow Transplant 16:751-771, 2010 761Stem Cell Signals in Alloreactive T Cellssuch as Oct4, Sox2, Klf4, Nanog, and c-Myc [56]
(Figure 5A; other data not shown). Furthermore, genes
associated with HSC self-renewal were decreased in
CD81 TE. For example, CD8
1 TE markedly downre-
gulated the expression of many genes related to recep-
tor, signaling, and transcription that are normally
expressed in HSCs, such Il6ra, Il6st, Smad4, Smad7,
and c-Myc (Table 6 and Figure 5A). Among them,
Smad4 and Smad7 have been shown to be required
for self-renewal and quiescence of HSCs [57].Role of Chromatin Modifying Enzyme Ezh2 in
CD81 T Cells
Data from previous studies demonstrate that the
loss of Ezh2 in mature T cells impairs their proliferative
response to anti-CD3 Ab [58]. We observed that Ezh2
mRNA and protein were significantly increased in al-
loreactive CD81TE (Figure 5B and C). Flow cytometry
analysis showed at the single cell level that all day 14
CD81 TE expressed higher levels of Ezh2 proteinthan TN (Figure 5D). Further tests using MSigDBv2
demonstrated that alloreactive CD81 TE activated 23
of 30 Ezh2 target or partner genes previously identified
by others [54] (Figure 6A). Ex vivo culture confirmed
that purified Ezh2-shRNA GFP1CD81 TN had re-
duced expression of Ezh2 protein (Figure 6B) and
decreased their expansion by approximate 4-fold in re-
sponse to anti-CD3 and anti-CD28 Abs compared to
Control-shRNA GFP1CD81 T cells (Figure 6C).
Thus, Ezh2 may play important roles in antigen-
activated CD81 T cells.
We further asked whether Ezh2 inhibition had dif-
ferential effects on alloantigen stimulated versus
homeostatic cytokine IL-7 mediated CD81T cell pro-
liferation. Because our previous studies suggest that
purified mouse T cells rapidly diminish in cultures in
the absence of DCs [30], we stimulated unfractionated
Ezh2-shRNA GFP1CD81TN with allogeneic DCs or
with IL-7. Five days later, cells were recovered from the
culture and analyzed for the expansion of GFP1CD81
T cells using flow cytometry. Interestingly, compared
Table 3. ESC-Related Genes That Are Activated in CD8+ TE
Gene Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
TMSC/TN TE/TN TMSC/TN TE/TN TMSC/TN TE/TN TMSC/TN TE/TN TMSC/TN TE/TN
Cell cycle Ubiquitin/Proteolysis/Proteasome Transcription/Transcription regulation Receptor/Signal transduction Microtubule-based process
Ccnb1 268697 2.28 16.85 Cdc20 107995 5.27 Mdfic 16543 2.77 18.58 Spp1 20750 4.52 Prc1 233406 1.86 12.05
Sgol1 72415 11.04 Capn2 12334 2.34 Prdm1 12142 10.62 Aurka 20878 4.47 Cks2 66197 4.85 11.65
Chek1 12649 2.6 10.34 Xpnpep1 170750 2.32 Tacc3 21335 6.06 Exo1 26909 4.02 Anln 68743 4.82
Cks1b 54124 2.58 9.51 Ide 15925 2.28 Csda 56449 5.52 Hif1a 15251 3.71 Dstn 56431 1.74
Cdkn1a 12575 9.17 Coq3 230027 1.67 2.12 Cdkn2b 12579 4.89 Csrp2 13008 3.01 Cytokinesis
Plk1 18817 7.54 Psma1 26440 1.99 Plagl1 22634 3.25 Sap30 60406 2.5 Igfbp7 29817 2.68
Aspm 12316 7.53 Psmb2 26445 1.55 1.78 Sub1 20024 2.62 Dusp16 70686 2.3 Wisp1 22402 2.26
Ect2 13605 6.86 Psmc2 19181 1.63 Myef2 17876 2.09 Rap2a 76108 2.27 Miscellaneous
Itgb1 16412 5.58 Psmb5 19173 1.62 Gtf2e2 68153 1.99 Bax 12028 1.84 Fignl1 60530 3.2 15.73
Ccne1 12447 5.31 Psmd6 66413 1.57 Tceb1 67923 1.95 Pex7 18634 1.6 1.74 Trip13 69716 1.88 8.69
Syce2 71846 5.16 Psma3 19167 1.55 Polr3k 67005 1.77 Bdnf 12064 1.72 Pcbp4 59092 6.39
Cdc25c 12532 4.72 Psma5 26442 1.55 Bzw1 66882 1.68 Gnb1 14688 1.69 Tmem49 75909 2.26 6.27
Ccnf 12449 3.96 Metabolism Cnot7 18983 1.63 Hnrpab 15384 1.65 Tacstd1 17075 5.17
Dlg7 218977 2.72 Gldc 104174 23.94 Klf9 16601 1.6 Ddx1 104721 1.65 Smoc2 64074 4.05
Cdkn2a 12578 2.55 Gsto1 14873 2.29 7.34 Mtdh 67154 1.57 Inhbb 16324 1.64 Synpo 104027 1.75 3.68
Mybl2 17865 2.43 Bcat1 12035 5.54 Nfyb 18045 1.52 Nasp 50927 1.61 Tipin 66131 3.5
Ran 19384 1.89 Myo5a 17918 1.55 4.68 RNA processing Sfrs1 110809 1.61 Ccdc99 70385 2.81
Ccng1 12450 1.84 Asns 27053 2.95 3.87 Syncrip 56403 1.79 2.88 Snrpd1 20641 1.55 Lactb2 212442 1.64 2.68
Erh 13877 1.67 1.74 Gcat 26912 2.71 Hnrpll 72692 2.73 Hrb 15463 1.55 Gmfb 63985 1.67 2.64
Psmd1 70247 1.69 Shmt1 20425 1.53 2.55 Ell2 192657 2.42 Rab1 19324 1.53 Wbp5 22381 2.42
Cops5 26754 1.64 Uxs1 67883 2.48 Ncbp2 68092 1.9 2.01 Vdac3 22335 1.52 Errfi1 74155 1.54 2.4
DNA replication/Repair Hmgcr 15357 1.96 Snrpa1 68981 1.91 Transport (Protein/Ion) Ccdc80 67896 2.34
Rrm2 20135 9.19 60.07 Pfkfb1 18639 1.8 Cstf3 228410 1.84 Kif20a 19348 4.26 Nucks1 98415 2.3
Cdc6 23834 5.09 21.54 Lypla1 18777 1.79 Sfrs3 20383 1.71 Arl5a 75423 3.8 Mpdu1 24070 1.85 2.29
Il1rl1 17082 19.15 Ywhah 22629 1.74 Cops2 12848 1.7 Snx10 71982 1.97 2.74 Ipp 16351 2.25
Dtl 76843 4.19 18.32 Acot9 56360 1.66 Lsm5 66373 1.7 Clic4 29876 2.31 2.56 Pls3 102866 2.16
Rad51 19361 2.92 15.71 Soat1 20652 1.65 Sfrs2 20382 1.65 Slc35b1 110172 2.15 Phlda3 27280 2.1
Pttg1 30939 8.1 Nup93 71805 1.62 Translation Arl1 104303 2.07 Dsp 109620 1.96
Dna2l 327762 1.68 7.48 Kpna3 16648 1.56 Farsb 23874 4.68 Lman1 70361 1.98 Prdx1 18477 1.91
Brca1 12189 2.04 5.87 Electron transport Mrpl27 94064 1.84 2.41 Vps54 245944 1.94 Tmem41b 233724 1.83
Smc2 14211 3.55 Nqo2 18105 3.3 Eif4e2 26987 1.52 2.04 Mtch2 56428 1.86 Rcn1 19672 1.6 1.77
Mcm2 17216 1.56 3.4 Etfb 110826 3.11 Eif1ay 66235 1.86 Snx5 69178 1.77 1.85 Esd 13885 1.73
Rfc5 72151 2.7 Pdia6 71853 1.6 2.42 Mrpl18 67681 1.69 Clcn5 12728 1.85 Psmc3ip 19183 1.71
Mcm3 17215 2.7 Gsr 14782 2.06 Eif3s1 78655 1.63 Slc2a3 20527 1.83 Ranbp1 19385 1.67
Mcm4 17217 2.59 Cyp51 13121 1.94 Mrpl16 94063 1.52 Nup62 18226 1.78 Nup85 445007 1.62
Nudt1 17766 1.66 2.53 Uqcrb 67530 1.92 Protein phosphorylation Slc33a1 11416 1.72 Ppp1r7 66385 1.62
Orc6l 56452 2.44 Txnl1 53382 1.81 Melk 17279 4.05 17.84 Golt1b 66964 1.7 Psmd7 17463 1.84 1.54
Rfc4 106344 2.4 Sqle 20775 1.69 Bub1 12235 7.69 Slc4a7 218756 1.69 Cox4nb 18117 1.54
Rpa3 68240 2.22 Txndc4 76299 1.6 Wee1 22390 2.07 6.06 Bcap29 12033 1.61 1.65 Asah1 11886 1.53
Dtymk 21915 1.65 2.21 Txnl5 52700 1.6 Ryk 20187 5.21 Slc12a2 20496 1.57 Uck2 80914 1.74 1.52
Hat1 107435 2.15 Chromatin modification/Assembly Plk4 20873 1.54 4.75 Inhibitorysignal/Apoptosis Tiprl 226591 1.51
Brca2 12190 2.01 Nusap1 108907 1.86 9.22 Ttk 22137 3.62 Ckap2 80986 5.44
Blm 12144 1.97 Mad2l1 56150 1.61 6.8 Mapk6 50772 2.07 Gas2 14453 4.73
Topbp1 235559 1.96 Tmem38b 52076 2.7 Chek2 50883 2.07 Cell adhesion/Communication
Ranbp5 70572 1.72 Nek2 18005 2.45 Ppap2a 19012 2.05 Adam19 11492 4.89
Dbf4 27214 1.69 Suv39h2 64707 2.04 Pigf 18701 1.61 Adam9 11502 2.82
Ube2n 93765 1.64 Cbx1 12412 1.94 Acp1 11431 1.56 Tnc 21923 1.94 1.56
Nudt5 53893 1.52 Nap1l1 53605 1.65 Ptprk 19272 1.54 Vcl 22330 1.66
Smarcad1 13990 1.56
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Table 4. NSC-Related Genes That Are Activated in CD8+ TE
Gene Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
TMSC/TN TE/TN TMSC/TN TE/TN TMSC/TN TE/TN TMSC/TN TE/TN TMSC/TN TE/TN
Cell cycle DNA replication/Repair Receptor/Signal transduction Transport (Protein/Ion) Transcription/Transcription regulation
Ccnb2 12442 3.64 29.94 Rrm2 20135 9.19 60.07 Epas1 13819 7.54 Sypl 19027 4.33 Mdfic 16543 2.77 18.58
Ccna2 12428 3.31 21.13 Cdc6 23834 5.09 21.54 Rhoc 11853 6.85 Kif20a 19348 4.26 Uhrf1 18140 2.89 9.26
Cdca5 67849 4.46 19.44 Dtl 76843 4.19 18.32 Rhoq 104215 1.69 5.32 Syt11 229521 2.9 3.88 Hells 15201 1.91 7
Ccnb1 268697 2.28 16.85 Uhrf1 18140 2.89 9.26 Arl5a 75423 3.8 Snx10 71982 1.97 2.74 Ezh2 14056 6.95
Sgol1 72415 11.04 Dna2l 327762 1.68 7.48 Hif1a 15251 3.71 Slc35b2 73836 2.61 Tacc3 21335 6.06
E2f8 108961 10.39 Lig1 16881 5.73 Nudt1 17766 1.66 2.53 Clic4 29876 2.31 2.56 Eomes 13813 1.61 5.7
Chek1 12649 2.6 10.34 Rpa2 19891 4.52 Sap30 60406 2.5 Pdzd11 72621 1.66 2.25 Csda 56449 5.52
Cks1b 54124 2.58 9.51 Rfc3 69263 1.6 4.27 Dusp16 70686 2.3 Slc35b1 110172 2.15 Cenpk 60411 4.51
Cdkn1a 12575 9.17 Rrm1 20133 4.18 Dtymk 21915 1.65 2.21 Dbi 13167 2.11 Nsbp1 50887 3.85
Plk1 18817 7.54 Mcm5 17218 4.07 Gpr56 14766 2.08 Lman1 70361 1.98 Klf10 21847 2.98
Aspm 12316 7.53 Smc2 14211 3.55 Akt1 11651 2.07 Vps54 245944 1.94 Wdhd1 218973 2.85
Ect2 13605 6.86 Fen1 14156 3.43 Arl1 104303 2.07 Gipc1 67903 1.55 1.93 Sub1 20024 2.62
Cdkn2c 12580 2.13 6.27 Prim1 19075 3.42 Arhgap21 71435 2 Arf4 11843 1.87 Pmf1 67037 2.45
Itgb1 16412 5.58 Mcm2 17216 1.56 3.4 Tank 21353 1.95 Mtch2 56428 1.86 Myef2 17876 2.09
Gmnn 57441 2.1 5.33 Hmgn2 15331 3.37 Fut8 53618 1.91 Snx5 69178 1.77 1.85 Rab8b 235442 2.09
Cdc45l 12544 1.68 5.13 Mcm7 17220 2.94 Rbl1 19650 1.83 Clcn5 12728 1.85 Gtf2e2 68153 1.99
Cdkn2b 12579 4.89 Prim2 19076 2.76 Tmpo 21917 1.82 Vps29 56433 1.83 Inppl1 16332 1.98
Cdc25c 12532 4.72 Rfc5 72151 2.7 Ptprj 19271 1.74 Rrbp1 81910 1.8 Cdca7l 217946 1.8 1.97
Pola1 18968 1.59 4.55 Mcm3 17215 2.7 Csnk2b 13001 1.73 Trappc1 245828 1.79 Tceb1 67923 1.95
Aurka 20878 4.47 Mcm4 17217 2.59 Ranbp5 70572 1.72 Ssr2 66256 1.73 Hnrpdl 50926 1.72 1.78
Ccnf 12449 3.96 Orc6l 56452 2.44 Gnb1 14688 1.69 Slc33a1 11416 1.72 Polr3k 67005 1.77
Gsg2 14841 1.75 3.11 Rfc4 106344 2.4 Dck 13178 1.66 Vps45 22365 1.72 Bzw1 66882 1.68
Dlg7 218977 2.72 Recql 19691 1.71 2.28 Ddx1 104721 1.65 Atp6v0a2 21871 1.71 Cnot7 18983 1.63
Nfatc1 18018 2.51 Rpa3 68240 2.22 Inhbb 16324 1.64 Slc4a7 218756 1.69 Sin3b 20467 1.63
Ran 19384 1.89 Smc6 67241 2.15 Tyms 22171 1.63 Slc39a6 106957 1.65 Mtdh 67154 1.57
Ccng1 12450 1.84 Hat1 107435 2.15 Aaas 223921 1.59 Bcap29 12033 1.61 1.65 Th1l 57314 1.53
Erh 13877 1.67 1.74 Blm 12144 1.97 Smap1 98366 1.58 Nup93 71805 1.62 Microtubule-based process
Rb1 19645 1.72 Topbp1 235559 1.96 Rab1 19324 1.53 Sfxn1 14057 1.7 1.57 Kif2c 73804 3.23 20.24
Psmd1 70247 1.69 Hmgb1 15289 1.82 Asna1 56495 1.53 Timm17b 21855 1.57 Kif11 16551 1.82 7.9
Cops5 26754 1.64 Ube2n 93765 1.64 Nudt5 53893 1.52 Kpna3 16648 1.56 Kif22 110033 2.33 7.45
Mapre1 13589 1.6 Smarcad1 13990 1.57 Cytokinesis Slc25a10 27376 1.56 Kif4 16571 3.58
Rap1a 109905 1.53 Prc1 233406 1.86 12.05 Kdelr2 66913 1.56 Mid1ip1 68041 2.07
Cks2 66197 4.85 11.65 Sec14l1 74136 1.54 Nde1 67203 2.04
Incenp 16319 4.68 Kif23 71819 1.68
Metabolism Ubiquitin/Proteolysis/Proteasome Skap2 54353 1.76 2.09 Chromatin modification/Assembly Pnkd 56695 2.29
Gldc 104174 23.94 Cdc20 107995 5.27 Protein phosphorylation Nusap1 108907 1.86 Mpdu1 24070 1.85 2.29
Brca1 12189 2.04 5.87 Capn2 12334 2.34 Melk 17279 4.05 17.84 Mad2l1 56150 1.61 Ipp 16351 2.25
Gpd2 14571 4.17 Xpnpep1 170750 2.32 Bub1 12235 7.69 Asf1b 66929 Tmem97 69071 2.24
Lycat 225010 3.06 Ide 15925 2.28 Wee1 22390 2.07 6.06 Nek2 18005 Pls3 102866 2.16
Gcat 26912 2.71 Psma1 26440 1.99 Ddr1 12305 2.26 5.82 Cbx5 12419 Dek 110052 2.16
Azin1 54375 2.29 Psmb1 19170 1.88 Stk39 53416 1.51 5.32 Pvt1 19296 1.57 Lancl2 71835 2.15
Pkm2 18746 2.19 Ube2l3 22195 1.82 Ryk 20187 5.21 Suv39h2 64707 Pqlc3 217430 2.14
Idh3a 67834 2 Blmh 104184 1.71 Plk4 20873 1.54 4.75 Cbx1 12412 Phlda3 27280 2.1
Gyg 27357 1.98 Ube2t 67196 1.64 Ttk 22137 3.62 Nap1l1 53605 Pih1d1 68845 1.59 2.03
Hmgcr 15357 1.96 Psmb4 19172 1.64 Mapk6 50772 2.07 Translation Anp32e 66471 1.96
Rpe 66646 1.86 Psmc2 19181 1.63 Cdk2 12566 1.87 Farsb 23874 4.68 Tmem30a 69981 1.92
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Ge Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
TMSC/TN TE/TN TMSC/TN TE/TN TMSC/TN TE/TN TMSC/TN TE/TN TMSC/TN TE/TN
Sd 67680 1.8 Ube2e3 22193 1.63 Commd1 17846 1.81 Lamp2 16784 2.63 3.48 Prdx1 18477 1.91
Ac 433256 1.79 Psmb5 19173 1.62 Ptp4a2 19244 1.74 Mrpl27 94064 1.84 2.41 Mlf2 30853 1.88
Ly 18777 1.79 Psmd6 66413 1.57 Rps6ka1 20111 1.73 Eif4e2 26987 1.52 2.04 Hccs 15159 1.85
De 67460 1.79 Psma3 19167 1.55 Ptpn9 56294 1.59 Eif1ay 66235 1.86 Actb 11461 1.84
Gs 14871 1.78 Psma5 26442 1.55 Ppp5c 19060 1.53 1.58 Mrpl13 68537 1.71 Tex9 21778 1.8
Yw h 22629 1.74 RNA processing Acp1 11431 1.56 Mrpl18 67681 1.69 Rcn1 19672 1.6 1.77
Gu 110006 1.72 Syncrip 56403 1.79 2.88 Inhibitory signal/Apoptosis Eif3s1 78655 1.63 Nubp1 26425 1.59 1.74
So 20652 1.65 Slbp 20492 2.76 Lgals1 16852 3.91 27.4 Mrpl16 94063 1.52 Psmc3ip 19183 1.71
Ay 210992 1.65 Hnrpll 72692 2.73 Birc5 11799 5.33 21.6 Miscellaneous Pdap1 231887 1.69
Ac 11428 1.58 Thoc4 21681 2.21 Casp3 12367 5.37 Fignl1 60530 3.2 15.73 Arpc5 67771 1.67
Pc a 13026 1.57 Cpsf2 51786 2.02 Gas2 14453 4.73 Trip13 69716 1.88 8.69 Ranbp1 19385 1.67
2.37 Pcbp4 59092
El ron transport Ncbp2 68092 1.9 2.01 Dap 223453 6.39 Tmem77 67171 1.65
Ac 11363 5.27 Snrpa1 68981 1.91 Bcl7c 12055 2.23 Sh3bgrl 56726 4.77 Pon2 330260 1.65
Pd 71853 1.6 2.42 Cstf3 228410 1.84 Api5 11800 2.16 Lxn 17035 4.32 Nup85 445007 1.62
Gs 14782 2.06 Rod1 230257 1.79 Casp7 12369 2.14 Capg 12332 1.95 4.17 Ppp1r7 66385 1.62
Cy 13121 1.94 Sfrs3 20383 1.71 Phlda1 21664 1.94 Ltb4dh 67103 4.01 Sephs2 20768 1.61
Uq 67530 1.92 Cops2 12848 1.7 Bax 12028 1.84 Gtse1 29870 3.59 Zdhhc6 66980 1.59
Gl 93692 1.87 Lsm5 66373 1.7 Bnip2 12175 1.51 Tipin 66131 3.5 Pdia3 14827 1.58
Tx 53382 1.81 Sfrs2 20382 1.65 Cell adhesion/Communication Ccdc99 70385 2.81 Mgat2 217664 1.56
Cy 66427 1.7 Sfrs1 110809 1.61 Itgb1 16412 5.58 Mtm1 17772 2.71 Psmd7 17463 1.84 1.54
Sq 20775 1.69 Regulation of cell growth/Proliferation Adam19 11492 4.89 Wbp5 22381 2.42 Psmc1 19179 1.54
Tx 4 76299 1.6 Scin 20259 3.06 Adam9 11502 2.82 Acyp2 75572 1.75 2.41 Asah1 11886 1.53
Cy 3 109754 1.57 Chpt1 212862 2.36 Tnc 21923 1.94 1.56 Nucks1 98415 2.3 Peci 23986 1.53
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Table 5. Functional Categories of 401 CD8+ TE-Related Stem Cell Genes (See Gene Symbols and Identification# in Table 3 and
Table 4)
Category Gene Symbols
1. Cell cycle regulation
Cell cycle (35) Ccna2, Cdca5, Ccnb1, Sgol1, E2f8, Chek1, Cks1b, Cdkn1a, Ncaph, Plk1, Aspm, Ect2, Cdkn2c, Gmnn, Ccne1, Syce2,
Cdc45l, Cdkn2b, Cdc25c, Pola1, Aurka, Ccnf, Gsg2, Dlg7, Cdkn2a, Nfatc1, Mybl2, Ran, Ccng1, Erh, Rb1, Psmd1,
Cops5, Mapre1, Rap1a
2. Resistance to stress
DNA replication/repair (34) Rrm2, Cdc6, Il1rl1, Dtl, Rad51, Uhrf1, Pttg1, Dna2l, Lig1, Rpa2, Rfc3, Rrm1, Mcm5, Smc2, Fen1, Prim1, Mcm2, Hmgn2,
Mcm7, Prim2, Mcm3, Rfc5, Mcm4, Orc6l, Rfc4, Recql, Rpa3, Smc6, Brca2, Blm, Topbp1, Hmgb1, Dbf4, Ube2n
Ubiquitin/proteolysis/proteasome (20) Cdc20, Coq7, Nedd4, Capn2, Xpnpep1, Ide, Coq3, Psma1, Psmb1, Ube2l3, Psmb2, Blmh, Ube2t, Psmb4, Psmc2,
Psmb5, Psmd6, Psma3, Psma5, Ube2e3
Metabolism (27) Gldc, Gsto1, Brca1, Bcat1, Myo5a, Gpd2, Lycat, Gcat, Shmt1, Uxs1, Azin1, Pkm2, Idh3a, Gyg, Hmgcr, Rpe, Pfkfb1,
Sdhb, Decr1, Acsl5, Lypla1, Gstt1, Gusb, Acot9, Aytl2, Soat1, Aco1
Electron transport (14) Acadl, Nqo2, Etfb, Pdia6, Gsr, Cyp51, Uqcrb, Glrx, Txnl1, Cyb5b, Sqle, Txndc4, Txnl5, Cyb5r3
3. Chromatin modification, and
transcription/translation regulation
Chromatin modification/assembly (12) Nusap1, Mad2l1, Asf1b, Tmem38b, Nek2, Cbx5, Pvt1, Hat1, Suv39h2, Cbx1, Nap1l1, Smarcad1
Transcription/transcription
regulation (33)
Mdfic, Prdm1, Uhrf1, Hells, Ezh2, Tacc3, Eomes, Csda, Cenpk, Nsbp1, Klf10, Wdhd1, Sub1, Sap30, Pmf1, Myef2,
Rab8b, Gtf2e2, Inppl1, Cdca7l, Tceb1, Rbl1, Tmpo, Hnrpdl, Polr3k, Cops2, Bzw1, Sin3b, Cnot7, Klf9, Mtdh, Th1l,
Nfyb
RNA processing (16) Syncrip, Slbp, Hnrpll, Ell2, Thoc4, Cpsf2, Ncbp2, Snrpa1, Cstf3, Rod1, Sfrs3, Lsm5, Sfrs2, Ddx1, Sfrs1, Snrpd1
Translation (11) Farsb, Lamp2, Mrpl27, Eif4e2, Lamc1, Ap3s1, Mrpl13, Mrpl18, Eif3s1, Dnajc9, Mrpl16
4. Survival/apoptosis
Survival/apoptosis (16) Lgals1, Birc5, Ckap2, Casp3, Gas2, Scin, Grn, Dap, Bcl7c, Api5, Casp7, Skap2, Phlda1, Bax, Nasp, Bnip2
5. Signaling
Protein phosphorylation (20) Melk, Bub1,Wee1, Ddr1, Stk39, Ryk, Plk4, Ttk, Mapk6, Chek2, Ppap2a, Cdk2, Commd1, Ptp4a2, Rps6ka1, Pigf, Ptpn9,
Ppp5c, Acp1, Ptprk
Receptor/signal transduction (24) Epas1, Rhoc, Rhoq, Hif1a, Grn, Dusp16, Rap2a, Gpr56, Akt1, Arhgap21, Tank, Gipc1, Fut8, Rrbp1, Csnk2b, Ssr2,
Ranbp5, Gnb1, Nup93, Nasp, Smap1, Timm17b, Kpna3, Rab1
6. Others
Transport (protein/ion) (33) Sypl, Kif20a, Syt11, Arl5a, Snx10, Slc35b2, Clic4, Slc35b1, Dbi, Arl1, Lman1, Vps54, Arf4, Mtch2, Clcn5, Snx5, Vps29,
Slc2a3, Trappc1, Nup62, Slc33a1, Vps45, Atp6v0a2, Golt1b, Slc4a7, Bcap29, Slc39a6, Aaas, Sfxn1, Slc12a2,
Slc25a10, Sec14l1, Asna1
Cell adhesion/communication (5) Itgb1, Adam19, Adam9, Vcl, Tnc
Microtubule-based process/
cytokinesis (12)
Kif2c, Kif11, Kif22, Kif4, Mid1ip1, Nde1, Kif23, Prc1, Cks2, Anln, Incenp, Dstn
Miscellaneous (89) Wisp1, Igfbp7, Chpt1, Fignl1, Trip13, Pcbp4, Tmem49, Tacstd1, Sh3bgrl, Spp1, Lxn, Capg, Smoc2, Exo1, Ltb4dh, Asns,
Synpo, Gtse1, Tipin, Plagl1, Ccdc99, Mtm1, Lactb2, Gmfb, Nudt1, Wbp5, Acyp2, Errfi1, Htatip2, Ccdc80, Nucks1,
Pnkd, Mpdu1, Ipp, Tmem97, Dtymk, Apaf1, Pls3, Dek, Lancl2, Pqlc3, Fyn, Phlda3, Pih1d1, Anp32e, Dsp, Tmem30a,
Prdx1, Mlf2, Hccs, Actb, Tmem41b, Tex9, Rcn1, Ptprj, Nubp1, Pex7, Ywhah, Esd, Bdnf, Psmc3ip, Nab1, Pdap1,
Arpc5, Ranbp1, Dck, Hnrpab, Tmem77, Pon2, Inhbb, Tyms, Nup85, Ppp1r7, Sephs2, Zdhhc6, Pdia3, Pcyt1a, Mgat2,
Kdelr2, Hrb, Psmd7, Psmc1, Cox4nb, Asah1, Peci, Uck2, Nudt5, Vdac3, Tiprl
TE indicates effector T cells;
Biol Blood Marrow Transplant 16:751-771, 2010 765Stem Cell Signals in Alloreactive T Cellsto Control-shRNA GFP1CD81 T cells, the expan-
sion of Ezh2-shRNA GFP1CD81 T cells was de-
creased in the culture supplemented with allogeneic
DCs but not with IL-7 (Figure 6D). This suggests
that Ezh2 may be required for antigen-driven T
cell responses rather than homeostatic T cell prolif-
eration.DISCUSSION
These studies identify a group of stem cell genes
that are normally expressed in ESCs and NSCs in
alloreactive CD81 T cells. Most of these stem cell
genes are found to be essential to cell cycle regulation,
DNA replication and repair, stress resistance, chroma-
tin modification, and transcription regulation. One of
these genes, Ezh2, emerges as an important regulator
for the proliferation of antigen-activated CD81 T
cells. On the other hand, alloreactive CD81 TE in-
crease the expression of many genes that mediate cellapoptosis and growth arrest. We demonstrate that
these alloreactive CD81 TE were rapidly diminished
in vivo in lethally irradiated secondary congenic recip-
ients, suggesting that homeostatic factors alone are not
sufficient to sustaining alloreactive CD81 TE. How-
ever, upon chronic exposure to alloantigens alloreac-
tive CD81 TE proliferate to persist in vivo despite
their massive apoptotic death. These data indicated
that although alloreactive CD81 TE were ‘‘terminally
differentiated’’ with drastically increased susceptibility
to apoptotic death, they had the ability to survive and
persist via the mechanisms of continuous replication
in the presence of alloantigens. Thus, these newly
identified stem cell genes could be important targets
for understanding and modulating allogeneic T cell re-
sponses and GVHD.
T cells are known to be stem cell-like cells [1,3,4].
Gene expression profile analysis reveals that memory
T cells may trigger HSC-related transcriptional pro-
grams to regulate their self-renewal in the absence of
antigens [17]. We found that alloreactive CD81 TE
Figure 5. Characterization of stem cell genes in alloreactive CD81 T cells. (A) The relative expression of stem cell genes in alloreactive CD81 TE and
CD81 TMSC are shown with genes identified by functional set enrichment analysis using curated gene lists from MSigDBv2 (Figure 4). (B) Real-time RT-
PCR analysis shows the relative mRNA expression of selected genes in each T cell subset. Data are representative of 3 independent preparations of
alloreactive T cells. (C) Western blot analysis shows the expression of EZH2 protein in purified day 14 CD81 TE, TMSC, and control TN. (D) donor
CD81 TN and day 14 CD8
1 T cells were stained with anti-Ezh2 Ab using intracellular staining and analyzed by flow cytometry. Dot plots show the
expression of Ezh2 in cell subset of donor T cells. Mean fluorescein intensity shows the amount of testing antigen.
766 Biol Blood Marrow Transplant 16:751-771, 2010K. Kato et al.activated stem cell transcriptional programs are oper-
ational in both ESCs and NSCs, whereas genes
decreased in CD81 TE were overrepresented in
HSC-enriched genes. Our observations were further
validated by our reanalyzing the gene expression
profile of Sarkar et al. [42], which revealed that ESC-
and NSC-related genes were activated in LCMV
gp33-specific CD81TE, but decreased in CD8
1mem-
ory T cells. It appears that functional T cell subsets can
be defined by different stem cell transcriptional pro-
grams that regulate their unique properties of TE
versus memory T cells. It is likely that alloreactive
CD81 TE require ESC- and NSC-related transcrip-
tional programs to generate a large number of
functionally active effectors sufficient to eliminate the
target antigen.
Interestingly, reactivation of stem cell transcrip-
tional programs occurs in both alloantigen-specific
CD81 TE generated during GVHD and viral
antigen-reactive CD81 TE derived from acuteinfection. We identified these CD81 TE-related
stem cell transcriptional programs using curated
gene lists from MSigDBv2 [40]. Although it has been
reported that stem cell transcriptional profiles identi-
fied by different groups do not correlate well with
each other [59], we found that approximately 30% of
the genes increased in our alloreactive CD81 TE are
present on ESC and/or NSC gene lists of Ramalho-
Santos et al. [41]. Other studies also clearly showed
a significant correlation of stem cell gene expression
profiles identified by different groups [41,60].
Furthermore, we independently validated that the
gene expression profiles of our alloreactive CD81 TE
were correlated significantly with those P14 CD81
TE of Sarkar et al. [42]. Thus, these CD8
1 TE-related
stem cell transcriptional programs may have signifi-
cant implications in regulating T cells across various
types of immune responses.
Overlapped gene expression profiles between
CD81TE and embryonic and neural stem cells suggest
Table 6. HSC-Enriched Genes That Are Decreased in CD8+ TE
Gene Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
Gene Symbol Gene ID#
Fold Change
TMSC/TN TE/TN TMSC/TN TE/TN TMSC/TN TE/TN TMSC/TN TE/TN TMSC/TN TE/TN
Cell cycle Translation Receptor/Signal transduction Regulation of cell growth/Proliferation Camsap1 227634 21.75
Lats2 50523 21.6 Mknk2 17347 21.62 Aplp2 11804 21.75 21.5 Ppan 235036 21.6 Las1l 76130 21.76
Rassf2 215653 21.64 Mrpl24 67707 21.75 Prpf6 68879 21.5 Creg1 433375 22.03 Pcf11 74737 21.78
Flcn 216805 22.1 Eif4g2 13690 21.55 21.8 Mettl3 56335 21.51 Pctk1 18555 22.09 Serpini1 20713 21.79
Sesn1 140742 22.71 25.69 Rpl37a 19981 22.18 Notch1 18128 21.51 Epc1 13831 22.03 22.28 Fnbp4 55935 21.81
DNA replication/Repair Rpl13 270106 22.57 Ikbkg 16151 21.52 Socs3 12702 22.41 Ccdc53 67282 21.85
Polg 18975 21.55 Rpl22 19934 22.59 Chd8 67772 21.52 Negative regulation
of transcription
Phf1 21652 21.86
E4f1 13560 21.63 Protein phosphorylation Rasa3 19414 21.54 from RNA polymerase II promoter Gtf2ird2 114674 21.87
Sfpq 71514 21.54 21.75 Tesk1 21754 21.59 Mapk14 26416 21.55 21.54 Cutl1 13047 21.52 Numa1 101706 21.57 21.88
Xpc 22591 22.52 Mast3 546071 21.59 Mfng 17305 21.56 Id3 15903 21.77 Brd1 223770 21.9
Nfix 18032 26.12 Prkcq 18761 21.64 Frap1 56717 21.57 Bcl6 12053 21.85 Plekha1 101476 21.91
Ubiquitin/Proteolysis/Proteasome Jak1 16451 21.52 21.75 Itpkb 320404 21.81 21.59 Tcf25 66855 22.02 Frmd6 319710 21.93 21.98
Usp3 235441 21.54 Csnk1g2 103236 21.75 Xab2 67439 21.59 Tle1 21885 23.63 Akap8l 54194 21.98
Fbxo38 107035 21.57 Ptpn21 24000 21.68 21.87 Dtx2 74198 21.77 21.6 Foxp1 108655 21.67 24.93 Grwd1 101612 21.99
Ubl4 27643 21.62 Prkce 18754 21.96 Dicer1 192119 21.77 21.63 Transport (Protein/Ion) Otud5 54644 21.99
Usp9x 22284 21.64 Map4k4 26921 22.44 Srpk2 20817 21.53 21.68 Mcfd2 193813 21.52 Etnk1 75320 22.02
Fbxo9 71538 21.72 Tec 21682 22.47 Mapk8 26419 21.58 21.73 Bet1l 54399 21.59 Abcf3 27406 22.03
Usp19 71472 21.66 21.85 Ikbke 56489 22.52 Stat6 20852 21.74 Abcb8 74610 21.61 Acyp1 66204 22.04
Rnpepl1 108657 21.56 22.04 Ptpn23 104831 22.87 Ppp2r5e 26932 21.76 Acox1 11430 21.65 Nsun4 72181 22.06
Ube2d2 56550 21.77 22.06 Prkd2 101540 22.98 Phc2 54383 21.78 Ecgf1 72962 21.65 Tmem141 51875 22.07
Rbbp6 19647 21.5 22.1 Transcription/Transcription regulation Rrad 56437 21.84 Pitpnm1 18739 21.76 Snord22 83673 22.07
Zfp292 30046 22.31 Zzz3 108946 21.51 Stub1 56424 21.84 Acadm 11364 21.82 Lrrc8a 241296 21.6 22.1
Rffl 67338 22.35 Zmynd11 66505 21.51 Arrb1 109689 21.87 Mybbp1a 18432 21.89 Paqr7 71904 21.68 22.1
Klk8 259277 24.21 Zkscan6 52712 21.53 Azi2 27215 21.74 21.91 Pitpnc1 71795 21.53 21.97 Cdc42se2 72729 21.56 22.12
Metabolism Nfe2l1 18023 21.53 Rai1 19377 21.61 21.91 Scamp1 107767 21.59 21.99 Bola2 66162 22.16
Tk2 57813 21.5 Ezh1 14055 21.55 Mfhas1 52065 21.98 Hcn3 15168 22.12 Crlf3 54394 21.55 22.21
Glb1l 74577 21.51 Scmh1 29871 21.56 Foxo3a 56484 21.99 P2rx4 18438 22.44 Zdhhc9 208884 22.26
Idua 15932 21.52 Zkscan3 72739 21.6 Spred2 114716 22.07 Ramp3 56089 22.54 Gas5 14455 22.3
Glul 14645 21.54 Zkscan1 74570 21.69 Gaa 14387 22.13 Laptm4b 114128 21.88 22.88 Tmem66 67887 22.33
Elovl6 170439 21.55 Rarg 19411 22.56 21.73 Dvl1 13542 22.15 Kcnn4 16534 23.1 Rbm38 56190 22.39
Supt6h 20926 21.61 Zfx 22764 21.73 Il16 16170 21.64 22.26 Rab3ip 216363 23.12 Jarid1b 75605 22.4
Pcyt2 68671 21.69 Mef2d 17261 21.77 Spsb1 74646 22.26 Slco3a1 108116 23.18 Marveld1 277010 22.47
Mthfr 17769 21.71 Ncor2 20602 21.6 21.81 Gbp2 14469 22.29 Slc12a7 20499 24.35 Ctdsp2 52468 21.94 22.56
Ndufa6 67130 21.85 Zfml 18139 21.79 22.05 Crebbp 12914 21.64 22.41 Abca1 11303 24.42 Armcx2 67416 -2.68
Pgs1 74451 22.1 Zfp96 22758 22.06 Macf1 11426 21.61 22.57 Ramp1 51801 21.68 217.13 Ipo4 75751 22.82
Ihpk1 27399 22.26 Zeb1 21417 22.11 Il4ra 16190 22.8 Miscellaneous Rabac1 14470 23.3
Cbr1 12408 22.55 Taf1a 21339 22.28 Ltb 16994 22.81 Tnip1 57783 21.69 21.51 Plekho1 67220 23.54
Lpin1 14245 22.57 Bach1 12013 21.55 22.34 Eng 13805 23.43 Nphp1 53885 21.52 Peli1 67245 21.94 24.03
Man2c1 73744 22.88 Klf3 16599 22.52 Smad4 17128 21.53 23.53 Isca1 69046 21.53 Btbd14a 67991 24.63
Gstk1 76263 22.99 Jmjd1a 104263 22.54 Il6st 16195 21.61 24.31 Msl2l1 77853 21.54 Rreb1 68750 27.28
Adcy6 11512 23.08 Basp1 70350 22.71 22.64 Smad1 17125 25.01 Nol1 110109 21.56 Cxxc5 67393 22.79 27.61
Dph5 69740 23.81 Ash1l 192195 21.83 22.84 Mettl4 76781 21.58 25.5 Dctn1 13191 21.56
Ldhb 16832 21.97 24.83 Zfp1 22640 22.91 Notch2 18129 21.58 25.62 Klhl7 52323 21.62
Pdk1 228026 26.29 Zbtb20 56490 22.61 23.08 Thra 21833 25.8 Sh3gl1 20405 21.63
RNA processing Dbp 13170 21.96 23.63 Inadl 12695 26.08 Mgea6 217615 21.65
Rpusd4 71989 21.51 Smad7 17131 21.87 23.68 Il6ra 16194 218.59 Bcl7b 12054 21.66
Imp3 102462 21.54 Irf6 54139 22.29 24.63 Cell adhesion/Communication Gltscr2 68077 21.7
Mphosph10 67973 21.62 Ssbp2 66970 26.88 Nisch 64652 21.74 22.16 Serf2 378702 21.7
Prpf38b 66921 21.65 Chromatin modification/Assembly Itga6 16403 21.67 23.24 Dhx30 72831 21.71
Nola3 66181 21.8 Chd1 12648 21.59 Cep350 74081 21.57 21.74
Utp20 70683 22.32 Smarca2 67155 22.44 Cramp1l 57354 21.78 21.74
HSC indicates hematopoietic stem cells.
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Figure 6. Identification of stem cell gene Ezh2 in alloreactive CD81 T cells. (A) The relative expression of 23 Ezh2 target or partner genes that were
also selected as increased in alloreactive CD81 TE relative to TN. (B) Western blot shows Ezh2 protein in CD8
1 TN expressing with Ezh2-shRNA or
Control-shRNA. These Ezh2-shRNA GFP1CD81 TN were derived from B6 mice reconstituted with HSCs infected by Ezh2-shRNA/GFP-pLVPT
off.
GFP1CD81 TN from B6 mice reconstituted with Con-shRNA/GFP-pLVPT
off were isolated as controls. (C) Sorted Ezh2-shRNA GFP1CD81 TN and
Control-shRNA GFP1CD81 TN (1  105/well, 96-well plate) were stimulated with anti-CD3Ab and anti-CD28 (2.5 mg/mL for each). Five days later,
cells were recovered and analyzed with flow cyotmetry for measuring GFP1CD81 T cells. (D) Unfractionated Ezh2-shRNAGFP1CD81 TN were stim-
ulated with BABL/c mouse-derived DCs, or with IL-7 alone. Five days later, cells were recovered and analyzed using flow cytometry for measuring
GFP1CD81 T cells. Fold change of GFP1CD81 T cells was calculated based on the output number of GFP1CD81 T cells after culture divided by
the input number of GFP1CD81 T cells before culture. Data shown in B, C, and D are representative of 2 independent experiments.
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ESCs and NSCs characterized in Ramalho-Santos’
et al. study are highly proliferating stem cells, whereas
HSCs are quiescent cells [41]. In their study, ESCs
were derived from the inner cell mass of the blastocyst
stage of embryos, whereas NSCs were isolated from
brain-derived neurospheres. Both ESCs and NSCs
were highly purified after ex vivo cultures for gene ex-
pression profile analyses. In contrast, HSCs were
freshly isolated from BM of normal B6 mice based
on dual-dye efflux and HSC markers [41]. We found
that many of these CD81 TE-related stem cell genes
were associated with cell cycle regulation, DNA repli-
cation and repair, and stress resistance. This was
in agreement with our findings that a proportion of
alloreactive CD81 TE continually proliferated uponchronic exposure to alloantigens. Thus, genes control-
ling proliferation of ESCs and NSCs are an important
component of the similarity between CD81 TE and
embryonic and neural stem cells.
However, CD81 TE did not increase the expres-
sion of genes associated with pluripotency of ESCs.
In contrast, they activated many other stem cell genes
that are found to be important for controlling cell
fate, differentiation, survival, self-renewal, and mem-
ory function in ESCs and NSCs, such as Uhrf1,Tacc3,
Hells, Birc5, and Ezh2 [37,49-54,61]. For example,
Ezh2 binds to chromatin and DNA during cell
dividing, thereby preserving transcriptional programs
and cell identity established during earlier response
phase [62,63]. We found that CD81 TE had the
ability to sustain their effector functions over
Biol Blood Marrow Transplant 16:751-771, 2010 769Stem Cell Signals in Alloreactive T Cellsnumerous rounds of cell dividing upon chronic
exposure to allogeneic stimuli. Previous reports have
also suggested that CD81 TE can become self-
renewing memory T cells upon clearance of the target
antigen [4-6,8,22]. These observations suggest
that CD81 TE share some common properties with
ESCs and NSCs in the expression of stem cell
transcriptional programs that are engaged in cell fate
decision, self-renewal, survival, differentiation, and
memory function.
Several lines of evidence suggest that Ezh2 may be
important for antigen-driven T cell responses. We
found that Ezh2 was abundantly expressed in antigen-
activated CD81 T cells but not in CD81 TN. Silencing
Ezh2 inhibited CD81 T cell proliferation activated by
TCR/CD28 costimulation and allogeneic DCs, which
is consistent with a previous report of others [58]. Inter-
estingly, knockdown of Ezh2 did not affect mature T
cells to proliferate in response to homeostatic cytokine
IL-7 alone. Thus, it is unlikely that inhibition of Ezh2
in alloreactive TE can globally affect donor T cell immu-
nity after allogeneic HSCT. However, further studies
are necessary to investigate the impact of Ezh2 inhibi-
tion in antigen-activated T cell responses and GVHD.
Our results suggest that APCs may play an impor-
tant role in regulating stem cell transcriptional pro-
grams in CD81 T cells. We found that alloreactive
CD81TE continuously replicated in secondary alloge-
neic recipients and caused severe GVHD, but rapidly
diminished in congenic recipients where alloantigens
were absent. Thus, allogeneic stimuli rather than ho-
meostatic factors are critical to the continuous replica-
tion in vivo of alloreactive CD81TE. This may explain
why APCs are important for alloreactive T cell-
mediated GVHD at both the induction and effector
phase [13,23,64-66]. Other studies suggest that
antigenic stimulation is also necessary for protective
immunity during chronic infection [67-69]. It is likely
that antigen stimulation sustains the replication of TE
through the activation of stem cell transcriptional
programs. However, other nonantigenic stimuli, such
as inflammatory cytokines and costimulatory signals,
could also be important for regulating stem cell
transcriptional programs in CD81 TE. For example,
CD41 T cells are found to be important for in vivo
development of long-lasting CD81 memory T cells
and are required for mediating chronic GVHD [70-
72]. It is possible that signals derived from CD41
help T cells might affect the expression of these stem
cell genes in antigen-activated CD81 T cells.
Stem cell transcriptional programs may also play
an important role in alloreactive CD81 TMSC. Gene
expression profile analysis showed that these CD81
TMSC were less differentiated as they did not produce
cytotoxic molecules and inflammatory cytokines. A re-
cent study suggests that activation of Wnt-signaling
arrests the effector differentiation, whereas it enhancesthe generation of CD81 TMSC with greater ability
than mature memory T cells to proliferate and gener-
ate tumor-reactive TE in vivo [21]. This further sup-
ports that CD81 TMSC themselves do not mediate
tissue injury, but can further differentiate into func-
tional CD81TE [15]. Notably, 70% of stem cell genes
activated in alloreactive CD81 TMSC remained in-
creased in CD81 TE. It will be interesting to deter-
mine how these ESC- and NSC-related genes affect
the proliferation and differentiation of CD81 TMSC.
In summary, we have identified that ‘‘terminally dif-
ferentiated’’ alloreactive CD81T cells activate stem cell
transcriptional programs that are normally expressed in
ESCs and NSCs. This group of stem cell genes may
play important roles in regulating the proliferation
and persistence of alloreactive T cells upon chronic ex-
posure to alloantigens in GVHD. Further exploring the
specific roles of ESC- and NSC-related stem cell genes
in chronically activated T cells could have significant
impact on understanding and modulating pathogenic
T cell responses in many other inflammatory condi-
tions, such as chronic infections, autoimmune diseases,
and rejection of grafted solid organs.ACKNOWLEDGMENTS
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